BIO
Price
$328.54
Change
-$16.06 (-4.66%)
Updated
Sep 20, 03:58 PM (EDT)
34 days until earnings call
PROF
Price
$7.84
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
41 days until earnings call
Ad is loading...

BIO vs PROF

Header iconBIO vs PROF Comparison
Open Charts BIO vs PROFBanner chart's image
Bio-Rad Laboratories
Price$328.54
Change-$16.06 (-4.66%)
Volume$2K
CapitalizationN/A
Profound Medical
Price$7.84
Change-$0.00 (-0.00%)
Volume$100.41K
CapitalizationN/A
View a ticker or compare two or three
BIO vs PROF Comparison Chart
Loading...
BIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
BIO vs. PROF commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and PROF is a StrongSell.

COMPARISON
Comparison
Sep 21, 2024
Stock price -- (BIO: $340.45 vs. PROF: $7.52)
Brand notoriety: BIO and PROF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BIO: 125% vs. PROF: 145%
Market capitalization -- BIO: $9.79B vs. PROF: $205.33M
BIO [@Medical Specialties] is valued at $9.79B. PROF’s [@Medical Specialties] market capitalization is $205.33M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 0 FA rating(s) are green whilePROF’s FA Score has 0 green FA rating(s).

  • BIO’s FA Score: 0 green, 5 red.
  • PROF’s FA Score: 0 green, 5 red.
According to our system of comparison, both BIO and PROF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 5 TA indicator(s) are bullish while PROF’s TA Score has 4 bullish TA indicator(s).

  • BIO’s TA Score: 5 bullish, 3 bearish.
  • PROF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BIO is a better buy in the short-term than PROF.

Price Growth

BIO (@Medical Specialties) experienced а +6.66% price change this week, while PROF (@Medical Specialties) price change was -5.41% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.46%. For the same industry, the average monthly price growth was +0.65%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

BIO is expected to report earnings on Oct 24, 2024.

PROF is expected to report earnings on Oct 31, 2024.

Industries' Descriptions

@Medical Specialties (+1.46% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIO($9.79B) has a higher market cap than PROF($205M). BIO YTD gains are higher at: 5.438 vs. PROF (-11.425). PROF has higher annual earnings (EBITDA): -26.78M vs. BIO (-654.76M). BIO has more cash in the bank: 1.61B vs. PROF (26.2M). PROF has less debt than BIO: PROF (7.94M) vs BIO (1.41B). BIO has higher revenues than PROF: BIO (2.67B) vs PROF (7.2M).
BIOPROFBIO / PROF
Capitalization9.79B205M4,778%
EBITDA-654.76M-26.78M2,445%
Gain YTD5.438-11.425-48%
P/E Ratio3.64N/A-
Revenue2.67B7.2M37,102%
Total Cash1.61B26.2M6,134%
Total Debt1.41B7.94M17,693%
FUNDAMENTALS RATINGS
BIO vs PROF: Fundamental Ratings
BIO
PROF
OUTLOOK RATING
1..100
1557
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
9693
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4982
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PROF's Valuation (49) in the null industry is in the same range as BIO (78) in the Medical Specialties industry. This means that PROF’s stock grew similarly to BIO’s over the last 12 months.

PROF's Profit vs Risk Rating (93) in the null industry is in the same range as BIO (96) in the Medical Specialties industry. This means that PROF’s stock grew similarly to BIO’s over the last 12 months.

BIO's SMR Rating (94) in the Medical Specialties industry is in the same range as PROF (98) in the null industry. This means that BIO’s stock grew similarly to PROF’s over the last 12 months.

BIO's Price Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for PROF (82) in the null industry. This means that BIO’s stock grew somewhat faster than PROF’s over the last 12 months.

BIO's P/E Growth Rating (86) in the Medical Specialties industry is in the same range as PROF (100) in the null industry. This means that BIO’s stock grew similarly to PROF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOPROF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
62%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend about 1 month ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
63%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
BIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PROF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BSJP23.150.02
+0.09%
Invesco BulletShares 2025 HY Corp Bd ETF
MISL30.90-0.01
-0.03%
First Trust Indxx Aerspc & Defns ETF
ATFV21.27-0.03
-0.16%
Alger 35 ETF
FINX27.43-0.06
-0.22%
Global X FinTech ETF
IEF98.53-0.43
-0.43%
iShares 7-10 Year Treasury Bond ETF

BIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIO has been closely correlated with RVTY. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIO
1D Price
Change %
BIO100%
+2.04%
RVTY - BIO
71%
Closely correlated
+1.53%
TMO - BIO
61%
Loosely correlated
-0.06%
WAT - BIO
57%
Loosely correlated
+1.34%
DHR - BIO
55%
Loosely correlated
-0.21%
A - BIO
52%
Loosely correlated
+0.48%
More

PROF and

Correlation & Price change

A.I.dvisor tells us that PROF and ALC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PROF and ALC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROF
1D Price
Change %
PROF100%
-2.15%
ALC - PROF
24%
Poorly correlated
-0.52%
BIO - PROF
24%
Poorly correlated
+2.04%
HSDT - PROF
23%
Poorly correlated
-2.51%
ANGO - PROF
23%
Poorly correlated
-0.52%
ZIMV - PROF
23%
Poorly correlated
-2.54%
More